Cybin Inc./$HELP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cybin Inc.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Ticker
$HELP
Sector
Primary listing
Employees
50
Headquarters
Toronto, Canada
Website
Cybin Inc. Metrics
BasicAdvanced
$234m
-
-$4.48
0.85
-
Price and volume
Market cap
$234m
Beta
0.85
52-week high
$9.83
52-week low
$4.15
Average daily volume
1.4m
Financial strength
Current ratio
13.778
Quick ratio
12.356
Interest coverage (TTM)
-40.86%
Profitability
EBITDA (TTM)
-119.249
Management effectiveness
Return on assets (TTM)
-31.95%
Return on equity (TTM)
-55.89%
Valuation
Price to book
0.85
Price to tangible book (TTM)
1.13
Price to free cash flow (TTM)
-1.129
Free cash flow yield (TTM)
-88.59%
Free cash flow per share (TTM)
-4.146
Growth
Earnings per share change (TTM)
9.57%
3-year earnings per share growth (CAGR)
-17.56%
Cybin Inc. News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs